NCT04818216View on ClinicalTrials.gov

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

January 3, 2022

Conditions
SARS-CoV-2 InfectionAcute Kidney Injury
Interventions
DRUG

Placebo

Placebo capsule containing inert ingredient

DRUG

Nicotinamide riboside

250 mg Nicotinamide riboside capsules

Trial Locations (4)

78229

The University of Texas Health Science Center at San Antonio, San Antonio

University Health Systems, San Antonio

98104

Harborview Medical Center, Seattle

10029-6574

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH